CryoLife Completes Acquisition of JOTEC

December 1, 2017 at 5:04 PM EST ATLANTA, Dec. 1, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts,…

Read More...

CryoLife Announces Enrollment of First Patients in BioGlue® Clinical Trial in China

November 6, 2017 at 5:04 PM EST ATLANTA, Nov. 6, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that enrollment has started in the Company’s BioGlue clinical trial in China.  The results from the trial will serve as the basis of the Company’s regulatory submission…

Read More...

CryoLife Reports Third Quarter 2017 Results

October 30, 2017 at 5:30 PM EDT ATLANTA, Oct. 30, 2017 /PRNewswire/ — Third Quarter and Recent Highlights: Announced Definitive Agreement to Acquire JOTEC Accelerated Enrollment in PerClot Clinical Trial Achieved Third Quarter Revenues of $44.0 Million Achieved GAAP Net Income of  $1.3 million, or $0.04 Per Fully Diluted Common Share; Non-GAAP Net Income of $2.6 Million, or $0.08 Per Fully Diluted Common Share…

Read More...

CryoLife Announces Release Date and Teleconference Call Details for 2017 Third Quarter Financial Results

October 17, 2017 at 5:04 PM EDT ATLANTA, Oct. 17, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 third quarter financial results will be released on Monday, October 30, 2017 after the market closes.  On Tuesday, October 31, 2017, the Company will hold a teleconference…

Read More...

CryoLife Announces Definitive Agreement to Acquire JOTEC

Visit JOTEC   Provides Access into $2 Billion Global Stent Graft Market with Highly Competitive Technologically Advanced Product Portfolio Adds Robust New Product Pipeline and Significantly Enhances R&D Capabilities Accelerates European Direct Strategy and Meaningfully Expands Cross-Selling Opportunities Expected to Drive High Single-Digit Revenue Growth with Gross Margin and Operating Margin Expansion Conference Call and…

Read More...

CryoLife Acquires On-X Life Technologies

ATLANTA, Jan. 20, 2016 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of On-X Life Technologies Holdings, Inc. (“On-X”), an Austin, Texas-based, privately held mechanical heart valve company. About CryoLife Headquartered in suburban Atlanta, Georgia,…

Read More...